Hypothesis

Administering dasatinib plus quercetin (D+Q) at the precise moment when senescent cell burden peaks after an acute insult yields greater clearance and longer‑lasting tissue repair than the current fixed‑day‑1 regimen.

Rationale

• Early senescence programs arise within hours of injury, but maximal p16^Ink4a^‑positive accumulation often occurs 48‑72 h later [4]. Treating at day 1 may therefore miss the window of highest susceptibility.
• D+Q acts via complementary pathways: dasatinib inhibits Src family kinases, quercetin blocks BCL‑xL and PI3K/AKT survival signaling [1]. Cells that have fully entered the senescent state up‑regulate these anti‑apoptotic nodes, making them more dependent on simultaneous inhibition.
• Hit‑and‑run exposure already shows sustained benefits when given as a short course [2, 3]. Aligning this exposure with the peak senescent load should amplify the downstream rise in geroprotective factors (α‑Klotho, Sirt‑1) and reduce the chance of senescent cell rebound.

Novel Mechanistic Insight

We propose that senescent cells pass through a “dependency shift”: early after stress they rely on transient DNA‑damage response kinases (ATM/ATR), whereas later they become addicted to Src‑BCL‑xL‑PI3K/AKT signaling for survival. Dasatinib’s Src inhibition alone is insufficient when cells are still dependent on ATM/ATR; quercetin’s BCL‑xL/PI3K blockade adds little value at that stage. Around 48‑72 h, the signaling rewires, creating a synthetic‑lethal interface where simultaneous Src and BCL‑xL/PI3K inhibition triggers apoptosis efficiently. Timing D+Q to this rewiring point should therefore lower the effective dose needed for clearance and limit off‑target effects.

Testable Predictions

1. Biomarker window – In a murine model of unilateral ureteral obstruction (UUO) or radiation‑induced lung injury, serial measurement of plasma SASP factors (IL‑6, CCL2) and tissue p16^Ink4a^ will show a peak at ~60 h post‑injury. D+Q given at this peak will reduce p16^Ink4a^ burden by >70 % versus day‑1 treatment (≈40 % reduction).
2. Geroprotective rebound – α‑Klotho and Sirt‑1 expression will rise earlier and reach higher peak levels when D+Q is timed to the senescence peak, correlating with improved functional outcomes (e.g., better creatinine clearance or lung compliance).
3. Dose‑sparing effect – Achieving comparable senolysis with a 50 % lower dasatinib dose (2.5 mg/kg) and quercetin dose (25 mg/kg) when administered at the peak window, indicating a therapeutic index improvement.
4. Rebound resistance – Mice receiving peak‑timed D+Q will show delayed re‑accumulation of p16^Ink4a^ cells (≥8 weeks) compared with early‑treatment groups, where senescence returns by 4 weeks.

Experimental Design

• Groups (n=10 per group): (a) vehicle, (b) D+Q day 1, (c) D+Q at biomarker‑defined peak (determined in a pilot cohort), (d) low‑dose D+Q at peak.
• Readouts: flow cytometry for p16^Ink4a^+ cells, SASP cytokine ELISA, kidney/lung histology, α‑Klotho & Sirt‑1 Western blot, functional assays (GFR, lung compliance, grip strength).
• Statistical test: Two‑way ANOVA with post‑hoc Tukey; falsify hypothesis if peak‑timed D+Q does not outperform day‑1 treatment by at least 20 % in senescent cell reduction (p<0.05).

Implications

If validated, this approach would transform senolytic prescribing from a static schedule to a dynamic, biomarker‑driven intervention, maximizing efficacy while minimizing drug exposure—addressing the field’s most glaring open problem: timing precision.